Clinical Trial

Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients

Study acronym: SASAN-SPARING
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Selective Bladder-Sparing Trial with Sasanlimab as Maintenance Treatment Based On Clinical Response To Neoadjuvant Treatment In Molecularly Categorized Muscle Invasive Bladder Cancer Patients
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-30.
Trial Details
NCT Number NCT06623162
Lead Sponsor Fundación de investigación HM
Collaborators: MFAR Clinical Research S.L., Hospital Universitario 12 de Octubre
Conditions Mibc, Muscle Invasive Bladder Cancer
Enrollment 70 participants
Start Date 2024-12
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-10-04